Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.80
+0.49
(+5.26%)
After-Hours: 04:02
Monte Rosa Therapeutics Net Income (Quarterly) : 3.063M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 3.063M |
| June 30, 2026 | -43.40M |
| March 31, 2026 | -44.50M |
| December 31, 2025 | -46.14M |
| September 30, 2025 | -27.08M |
| June 30, 2025 | -12.30M |
| March 31, 2025 | 46.88M |
| December 31, 2024 | 13.44M |
| September 30, 2024 | -23.86M |
| June 30, 2024 | -30.31M |
| March 31, 2024 | -31.97M |
| December 31, 2023 | -33.25M |
| September 30, 2023 | -34.88M |
| June 30, 2023 | -35.18M |
| Date | Value |
|---|---|
| March 31, 2023 | -32.04M |
| December 31, 2022 | -30.78M |
| September 30, 2022 | -27.32M |
| June 30, 2022 | -26.47M |
| March 31, 2022 | -23.93M |
| December 31, 2021 | -23.44M |
| September 30, 2021 | -19.84M |
| June 30, 2021 | -18.40M |
| March 31, 2021 | -12.28M |
| December 31, 2020 | -19.66M |
| September 30, 2020 | -6.558M |
| June 30, 2020 | -5.364M |
| March 31, 2020 | -4.302M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp. | 258.60M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 54.37M |
| Total Expenses (Quarterly) | 51.30M |
| EPS Diluted (Quarterly) | 0.0282 |
| Enterprise Value | 253.90M |
| Gross Profit Margin (Quarterly) | 96.06% |
| Profit Margin (Quarterly) | 5.63% |
| Earnings Yield | -16.64% |
| Normalized Earnings Yield | -16.64 |